Document is current
Any future updates will be listed below
-
Authors
Zhang, Dingpeng https://orcid.org/0000-0001-9652-0067
Duque-Jimenez, Jhoely https://orcid.org/0009-0006-5796-2704
Facchinetti, Francesco https://orcid.org/0000-0001-6313-6341
Brixi, Garyk https://orcid.org/0000-0002-1253-0522
Rhee, Kaitlin https://orcid.org/0000-0003-0168-8946
Feng, William W. https://orcid.org/0000-0002-8976-5020
Jänne, Pasi A. https://orcid.org/0000-0002-7821-4928
Zhou, Xin https://orcid.org/0000-0002-8198-2856
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 14 August 2024
First Online: 25 September 2024
Competing interests
: X.Z., D.Z. and K.R. have filed patent applications for the TransTAC technology. P.A.J. has received consulting fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, LOXO Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Takeda Oncology, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai, Biocartis, Allorion Therapeutics, Accutar Biotech, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, Duality, Dizal Pharma and Abbvie; post-marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp; sponsored research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer-Ingelheim, Eli Lilly and Company, Revolution Medicines and Astellas Pharmaceuticals; and stock ownership in Gatekeeper Pharmaceuticals.
